Pancreatic Cancer Clinical Trial
— PORSCHOfficial title:
POstopeRative Standardization of Care: THe Implementation of Best Practice After Pancreatic Resection. a Nationwide Stepped-Wedge Cluster Randomized Trial
This Nationwide stepped-wedge cluster randomized trial is designed to evaluate if the implementation of a best practice algorithm for postoperative care results in a decrease in incidence of major complications and death after pancreatic resection as compared to current practice.
Status | Recruiting |
Enrollment | 1600 |
Est. completion date | February 9, 2020 |
Est. primary completion date | November 9, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion Criteria for Clusters: - All Dutch centers performing pancreatic surgery (i.e. performing at least 20 pancreatoduodenectomies a year) Exclusion Criteria for Clusters: - None Inclusion Criteria for Patients: - Patients underoging pancreatic resection for any indication Exclusion Criteria for Patients: - None (i.e. complete enumeration) |
Country | Name | City | State |
---|---|---|---|
Netherlands | Jeroen Bosch Ziekenhuis | 's Hertogenbosch | |
Netherlands | Academic Medical Center | Amsterdam | |
Netherlands | Onze Lieve Vrouwen Gasthuis | Amsterdam | |
Netherlands | VUmc | Amsterdam | |
Netherlands | Amphia ziekenhuis | Breda | |
Netherlands | Reinier de Graaf gasthuis | Delft | |
Netherlands | Catharina ziekenhuis | Eindhoven | |
Netherlands | Medisch Spectrum Twente | Enschede | |
Netherlands | UMCG | Groningen | |
Netherlands | Tjongerschans | Heerenveen | |
Netherlands | LUMC | Leiden | |
Netherlands | Maastricht UMC | Maastricht | |
Netherlands | Radboud UMC | Nijmegen | |
Netherlands | Erasmus MC | Rotterdam | |
Netherlands | Maasstad ziekenhuis | Rotterdam | |
Netherlands | RAKU (St. Antonius ziekenhuis & UMC Utrecht) | Utrecht | |
Netherlands | Isala klinieken | Zwolle |
Lead Sponsor | Collaborator |
---|---|
St. Antonius Hospital | Dutch Cancer Society |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Composite primary endpoint | The primary endpoint of this trial is a composite of the most severe complications associated to postoperative pancreatic fistula. This endpoint will be considered positive if one of the following complications occurs within 90 days after pancreatic resection: late postpancreatectomy bleeding, new-onset organ failure and/or death | 90 days after index pancreatic resection | |
Secondary | Postoperative mortality | Measured as rate of death at 90-day follow-up | 90 days after index pancreatic resection | |
Secondary | New-onset organ failure | Measured as organ failure occuring any time within 90 days after resection, not present at time of index pancreatic resection. | 90 days after index pancreatic resection | |
Secondary | Late postpancreatectomy bleeding | Defined in accordance to the International Study Group on Pancreatic Surgery (ISGPS) definition as bleeding occurring any time after 24 hours after pancreatic resection. | 90 days after index pancreatic resection | |
Secondary | Postoperative morbidity | Including complications according to the Clavien-Dindo system and pancreatectomy specific complications according to the ISGPS definitions (e.g. postpancreatectomy bleeding, postoperative pancreatic fistula, postoperative bile leak, postoperative chyle leak and delayed gastric emptying). | 90 days after index pancreatic resection | |
Secondary | Adjuvant chemotherapy | Measured as number of patients receiving adjuvant chemotherapy at 90-day follow-up | 90 days after index pancreatic resection | |
Secondary | Success of implementation | Measured as number of patients in whom the algorithm was not followed and timing of abdominal CT scans in both strategies. | 90 days after index pancreatic resection | |
Secondary | Cost-effectiveness | Calculated by comparing health effects and medical costs related to both strategies up to 90 days after pancreatic resection. | 90 days after index pancreatic resection |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05305001 -
Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
Recruiting |
NCT06054984 -
TCR-T Cells in the Treatment of Advanced Pancreatic Cancer
|
Early Phase 1 | |
Recruiting |
NCT04927780 -
Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
|
Phase 3 | |
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Terminated |
NCT03140670 -
Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy
|
Phase 2 | |
Terminated |
NCT00529113 -
Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
|
Phase 1 | |
Recruiting |
NCT05168527 -
The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05391126 -
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
|
N/A | |
Terminated |
NCT03300921 -
A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer
|
Phase 1 | |
Completed |
NCT03153410 -
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
|
Early Phase 1 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05679583 -
Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer
|
Phase 2 | |
Recruiting |
NCT04183478 -
The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer
|
Phase 2/Phase 3 | |
Terminated |
NCT03600623 -
Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer
|
Early Phase 1 | |
Recruiting |
NCT04584008 -
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
|
N/A | |
Recruiting |
NCT05351983 -
Patient-derived Organoids Drug Screen in Pancreatic Cancer
|
N/A | |
Completed |
NCT04290364 -
Early Palliative Care in Pancreatic Cancer - a Quasi-experimental Study
|